![]() |
||||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
VOLUME 3, NUMBER 9 |
AUGUST 6, 2012 |
![]() |
||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
WHAT SHOULD I KNOW ABOUT WARM COMPRESS THERAPY WHEN TREATING PATIENTS WITH MEIBOMIAN GLAND DYSFUNCTION (MGD)? |
![]() |
![]() |
![]() |
||||||||||
Keep in mind that it is important to apply sustained moist heat when treating MGD. To optimize the efficiency of warm compress therapy, patients should heat the compresses to 45°C, optimize contact with the outer eyelid surface, and maintain consistent pressure for at least four minutes to achieve an inner lower eyelid temperature greater than or equal to 40°C. |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
"The greatest management principle in the
world is: The things that get rewarded and appreciated get done."
|
![]() |
||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Review of Optometry® is published by the Professional Publications Division of Jobson
Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA
19073. To subscribe to other JMI newsletters or to manage your subscription, click here. To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address. To ensure delivery, please be sure to add revoptom@lists.jobsonmail.com to your address book or safe senders list. Click here if you do not want to receive future emails from Review of Optometry. |